Press Release

Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference

March 14, 2018

NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that Dan Wechsler, President and CEO of Melinta, will be presenting at Needham & Company’s 17th Annual Healthcare Conference in New York, NY. Mr. Wechsler’s presentation will take place on Tuesday, March 27, 2018 at 12:45pm Eastern Time. A live and archived webcast of the presentation will be accessible from the Melinta Events & Presentations section of the Investors webpage.

Needham & Company’s Annual Healthcare Conference is host to over 130 public and private companies across the life sciences sectors. It is taking place March 27-28, 2018 at the Westin Grand Central Hotel in New York, NY.

About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit for more information.

For More Information:

Media Inquiries:
Amra Maynard
(917) 302-2702

Investor Inquiries:
Lisa DeFrancesco
(847) 681-3217

Raj Mistry
(312) 801-2051

Primary Logo


Source: Melinta Therapeutics

Melinta Therapeutics, Inc. ©2019 ALL RIGHTS RESERVED | Terms of Use